Takeda files for Japanese approval of brentuximab
This article was originally published in Scrip
Executive Summary
Takeda has applied for the approval of brentuximab vedotin in Japan, for the treatment of adults with relapsed or refractory CD30-positive Hodgkin lymphoma or relapsed/refractory CD30-positive anaplastic large cell lymphoma.